文献速递免疫规划慢病防控与筛查

接受免疫检查点抑制剂治疗的成人接种季节性流感疫苗的安全性:基于行政数据的自身对照病例系列研究

The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data.
PubMed 文献 · Vaccine · 2024-02-09

该研究利用加拿大安大略省2012至2019年行政数据,对接受免疫检查点抑制剂(ICI)治疗的癌症成人进行自身对照病例系列分析,比较接种流感疫苗后1-42天风险期与接种前对照期的急诊就诊和/或住院发生率。结果显示风险期与对照期发生率相似,发生率比1.04(95%CI:0.75-1.45),未发现接种与严重免疫相关不良事件风险增加相关。

要点

  • 在1133例接受ICI治疗的癌症成人中,流感疫苗接种后1-42天急诊就诊和/或住院发生率与对照期相似,发生率比1.04(95%CI:0.75-1.45)。
  • 亚组和敏感性分析结果与主分析相似。
  • 研究结果支持流感疫苗在ICI治疗成人中安全性的进一步证据。

核心结论

  • 季节性流感疫苗接种与接受ICI治疗的癌症成人急诊就诊或住院发生率增加无关,研究结果支持疫苗安全性的进一步证据。

研究设计与样本

  • 使用加拿大安大略省2012至2019年行政数据,对接受ICI治疗并接种流感疫苗的癌症成人进行自身对照病例系列研究,共识别1133条记录。

主要发现

  • 研究人群多数年龄≥66岁(73%)、男性(63%)、肺癌(54%)、使用程序性细胞死亡蛋白1(PD-1)抑制剂(91%)。
  • 26%的观察期间发生急诊就诊和/或住院。
  • 风险期与对照期急诊就诊和/或住院发生率相似,发生率比1.04(95%CI:0.75-1.45)。
  • 亚组和敏感性分析结果相似。

关键数值与推荐

  • 接种前对照期:ICI启动后42天至疫苗接种前14天;风险期:疫苗接种后1-42天;接种后对照期:风险期后至ICI停药或最长两年。
  • 严重免疫相关不良事件定义为ICI启动后任何原因的急诊就诊和/或住院。
  • 采用固定效应泊松回归模型,校正季节性和日历时间,估计风险期与对照期之间免疫相关不良事件的相对发生率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitor (ICI) therapy for patients undergoing cancer treatment carries a risk of severe immune-related adverse events (IRAEs). Questions remain about whether seasonal influenza vaccination might increase the risk of developing IRAEs among these patients given that vaccines are immunomodulatory. Previous vaccine safety studies on patients with cancer prescribed ICI therapy have demonstrated conflicting results. METHODS: Using health administrative data from Ontario, Canada among adults diagnosed with cancer who had been prescribed ICI therapy and who had received an influenza vaccine from 2012 to 2019, we conducted a self-controlled case series study. The pre-vaccination control period started 42-days post-ICI initiation until 14-days prior to vaccination, the risk period was 1-42 days post-vaccination, and the post-vaccination control period was after the risk period until ICI discontinuation or a maximum period of two years. Emergency department (ED) visit(s) and/or hospitalization for any cause after ICI initiation was used to identify severe IRAEs. We fitted a fixed-effects Poisson regression model accounting for seasonality and calendar time to estimate relative incidence of IRAEs between risk and control periods. RESULTS: We identified 1133 records of cancer patients who received influenza vaccination while prescribed ICI therapy. Most were aged ≥ 66 years (73 %), were male (63 %), had lung cancer (54 %), and had received ICI therapy with a programmed cell death protein 1(PD-1) inhibitor (91 %). A quarter (26 %) experienced an ED visit and/or hospitalization during the observation period. Rates of ED visits and/or hospitalizations in the risk vs. control periods were similar, with an incidence rate ratio of 1.04 (95 % CI: 0.75-1.45). Subgroup and sensitivity analyses yielded similar results. CONCLUSION: Seasonal influenza vaccination was not associated with an increased incidence of ED visit or hospitalization among adults with cancer treated with ICI therapy and our results support further evidence of vaccine safety.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Grima AA, Kwong JC, Richard L, et al. The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data. Vaccine. 2024. PMID: 38341288. doi:10.1016/j.vaccine.2024.01.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。